Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers

Podobne zapisy

• Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
  od: Martin, Jovana Y., i wsp.
  Wydane: (2016)
• Phase II Study of Bevacizumab and Pemetrexed for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
  od: Hagemann, Andrea R., i wsp.
  Wydane: (2013)
• OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
  od: Aghajanian, Carol, i wsp.
  Wydane: (2012)
• A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
  od: Nagao, Shoji, i wsp.
  Wydane: (2020)
• Safety and Efficacy of Video Laparoscopic Surgical Debulking of Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
  od: Nezhat, Farr R., i wsp.
  Wydane: (2012)